Company Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc. Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 ESMO Congress


Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) announced preliminary efficacy data for RX-3117 in an ongoing Phase Ib/IIa clinical trial in patients with metastatic pancreatic cancer  and provided an update on the Phase I clinical trial with Supinoxin (RX-5902) at the 2016 European Society for Medical Oncology (ESMO) Congress in Copenhagen, Denmark.

“The RX-3117 clinical data are very encouraging, since there are no approved treatments for pancreatic cancer patients who have failed two or more prior therapies. Current options for these patients are usually limited to palliative or best supportive care. Having patients who show responses beyond 4 months in this refractory patient population is certainly very exciting,” said Ely Benaim, M.D., Chief Medical Officer for Rexahn.

“RX-3117 is a novel oral antimetabolite that has shown interesting clinical activity against several cancers, including pancreatic cancer.  I am encouraged by the current data and look forward to the additional data being generated in stage 2 of the ongoing Phase Ib/IIa clinical trial in pancreatic cancer patients,” commented Manish A. Shah, M.D., Director, Gastrointestinal Oncology Program, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.

RX-3117 Phase Ib/IIa clinical data

The preliminary efficacy data for RX-3117 from an ongoing Phase Ib/IIa clinical trial in metastatic pancreatic cancer  were presented on Monday October 10, 2016 in a poster presentation entitled “RX-3117, An Oral Antimetabolite to Treat Advanced Solid Tumors (ST): Phase 1 and Ongoing Phase 2a Results” authored by Drs. Drew Rasco (South Texas Accelerated Research Therapeutics, San Antonio, TX), Jaime R. Merchan (Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL) and Rexahn Collaborators.

Patients enrolled into stage 1 of the clinical trial had actively progressing disease with 88% of them having received 4 or more prior cancer therapies (including 5-FU and gemcitabine-based therapies). These patients would usually be offered palliative or best supportive care. There are no approved treatments for pancreatic cancer patients who have failed three or more prior therapies and their survival is usually less than 2 months. In the current study more than 20% of patients treated with RX-3117 exhibited progression free survival of greater than 4 months. An additional 20%, for a total of 40%, of the patients exhibited progression free survival of 2.5 months.  RX-3117 was shown to be safe and well tolerated in this patient group. The most frequently reported drug related adverse events were mild to moderate fatigue, diarrhea and decreased white blood cell counts. Stage 1 of the clinical study is still on-going. However, since the predefined efficacy criteria have been achieved, stage 2 of the study has been initiated.

The ongoing Phase Ib/IIa clinical trial is a multicenter, open-label single-agent study of RX-3117 being conducted at 10 clinical centers in the United States. Patients receive a 700 mg daily oral dose of RX-3117, five times weekly on a three weeks on, one week off dosing schedule in a 28 day cycle for up to eight treatment cycles, or until their disease progresses. The study follows a two-stage design.  In stage 1 of the trial, up to 10 patients with relapsed or refractory metastatic pancreatic cancer were enrolled.  Based on predefined criteria, if 20% or more of the patients have progression free survival of > 4 months, or an objective clinical response rate and reduction in tumor size, then an additional 40 pancreatic cancer patients can be enrolled into stage 2.

Supinoxin Phase I clinical data

Clinical data from the ongoing Phase I clinical trial with Supinoxin were presented on Monday October 10, 2016  in a poster presentation entitled “Phase 1/2a Study of RX-5902 in Advanced Solid Tumors (ST): an Orally Bioavailable Inhibitor of Phosphorylated p68 and Modulator of β-Catenin Nuclear Translocation” authored by Drs. S. Gail Eckhardt (University of Colorado Cancer Center), W. Larry Gluck (Translational Oncology Research, Greenville, SC), Martin Gutierrez (John Theurer Cancer Center, Hackensack University Medical Center, NJ) and Rexahn collaborators.

The updated results from the ongoing Phase I clinical trial continue to show intriguing evidence of single-agent, clinical activity of Supinoxin. Supinoxin is safe and well tolerated at the doses and dosing schedules tested with no dose limiting toxicities or treatment-related serious adverse events. The most frequently reported drug related adverse events were mild nausea, vomiting and fatigue. Initial signs of clinical activity have been observed in patients with breast, neuroendocrine, paraganglioma, head and neck and colorectal cancers, demonstrating stable disease for up to 880 days. Of these patients approximately 55% had received four or more therapies prior to their enrollment in the Phase I clinical study. The study protocol has recently been amended to target triple negative breast cancer patients in a 2-stage Phase IIa design. (Original Source)

Shares of Rexahn Pharmaceuticals closed last Friday at $0.21, down $0.00 or -1.41%. RNN has a 1-year high of $0.52 and a 1-year low of $0.20. The stock’s 50-day moving average is $0.24 and its 200-day moving average is $0.27.

On the ratings front, FBR analyst Vernon Bernardino reiterated a Buy rating on RNN, in a report issued on September 12. According to TipRanks.com, Bernardino has a yearly average return of -15.4%, a 26% success rate, and is ranked #4072 out of 4183 analysts.

Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It dedicates to the discovery, development and commercialization of innovative treatments for cancer and other medical needs. The company currently has three clinical stage oncology candidates, Archexin, RX-3117, and Supinoxin and a robust pipeline of preclinical compounds to treat multiple types of cancer. It has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D gold and times.